Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.48, $0.03 worse than the analyst estimate of $0.51. Revenue for the quarter came in at $3.82 billion versus the consensus estimate of $3.73 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.